• Platelets express retinoic acid receptor (RAR)a protein, specifically binding target mRNAs.
Summary. Background: Translational control mechanisms in platelets are incompletely defined. Here, we determined whether the nuclear transcription factor RARa controls protein translational events in human platelets. Methods: Isolated human platelets were treated with the pan-RAR agonist all-trans-retinoic acid (atRA). Global and targeted translational events were examined. Results: Stimulation of platelets with atRA significantly increased global protein expression. RARa protein bound to a subset of platelet mRNAs, as measured by next-generation RNAsequencing. In-depth analyses of 5 0 and 3 0 -untranslated regions of the RARa-bound mRNAs revealed consensus RARa binding sites in microtubule-associated protein 1 light chain 3 beta 2 (MAP1LC3B2), SLAIN motif-containing protein 2 (SLAIN2) and angiopoietin-1 (ANGPT1) transcripts. When platelets were treated with atRA, binding interactions between RARa protein and
Introduction
Platelets are small anucleate cells critical for the formation of hemostatic plugs [1] . Because they lack a nucleus, platelets have traditionally been considered simple 'sacs of glue' with limited functionality beyond acute hemostasis. In recent years, however, numerous studies have shown that platelets possess nuclear proteins, such as the peroxisome proliferator-activated receptor (PPAR)-c [2] [3] [4] [5] . In addition, platelets maintain a broad repertoire of nuclear functions, including the capacity to process premRNAs [6] [7] [8] [9] , process pre-miRNAs [10] and translate mRNA into protein [11] .
Retinoids are a group of naturally occurring vitamin A derivatives that regulate cellular differentiation and growth [12] . The retinoid receptors are members of the complex nuclear receptor system and they control transcription in nucleated cells [13] . The family of retinoid receptors includes the retinoid A receptors (RAR) -a, -b and -c and the retinoid X receptors (RXR) -a, -b and -c [14] . These RAR and RXR isoforms differ with respect to ligand affinity and tissue distribution. Vertebrates require the vitamin A metabolite alltrans-retinoic acid (atRA) for reproduction, development, growth and survival [15] . atRA signals through RAR, whereas the stereoisomer of atRA, 9-cis retinoic acid , is a high-affinity ligand for RXR [16, 17] .
Although retinoid receptors are ubiquitously expressed in nucleated cells, an understanding of their presence and function within platelets is much more limited. This is a clinically relevant question to address, as the therapeutic use of atRA in patients is associated with alterations in the platelet count, a hypercoagulable state and thrombosis [18, 19] . Two studies demonstrated that human platelets possess RXR protein and release it upon activation [4, 5] . Moreover, RXR-PPARc complexes have been identified in platelet-derived microparticles (PMPs) [5] and non-genomic signaling through RXR inhibits platelet aggregation [4] . In 2016, our group reported that atRAmediated signaling through RARa controls actin cytoskeletal events in platelets [20] .
Here we investigated whether RARa regulates protein synthesis in human platelets. We show that RARa specifically binds a subset of mRNAs, inducing a translational block, and these interactions are significantly reduced in platelets treated with atRA. We also demonstrate that atRA markedly increases the expression of microtubuleassociated protein 1 light chain 3 beta 2 (MAP1LC3B2). These discoveries identify a previously unknown mechanism of translational control in human platelets.
Materials and methods

Platelet isolation and culture
All studies were approved by the University of Utah IRB (Protocol #000392). Leukocyte-depleted platelets were isolated from healthy, medication-free consenting subjects as previously described [6, 7, [21] [22] [23] . These methods yield platelet preparations that are > 99% pure. Briefly, whole blood was drawn into acid-citrate-dextrose (1.4 mL ACD/8.6 mL blood) through a standard venipuncture technique and used immediately upon collection. Whole blood was first centrifuged at 150 9 g for 20 min at 20°C to separate platelet-rich plasma (PRP) from red and white blood cells. Red and white blood cells were carefully removed from the PRP. The PRP was then centrifuged again at 1500 9 g for 20 min at 20°C to separate plasma from the platelets. Washed platelets were resuspended at 1 9 10 8 mL À1 in serum-free M199 medium, placed in round-bottom polypropylene tubes (Becton Dickinson, Franklin Lakes, NJ, USA), and cultured in a 37°C humidified incubator for different time-points. In select studies, platelets were treated with all-trans retinoic acid (atRA, 10 lM), 9-cis retinoic acid (9cisRA, 10 lM) or their vehicle (DMSO) (Sigma, St. Louis, MO, USA).
Next generation RNA-sequencing RNA was isolated from leukocyte-depleted platelets or RARa precipitates as previously described [23] [24] [25] [26] .
Briefly, platelets (~1 9 10 9 mL À1 ) were lysed in Trizol (Invitrogen, Eugene, OR, USA). Isolated RNA was resuspended in RNAse free dH 2 0, treated with TurboDNAse (Ambion, Waltham, MA, USA), and then precipitated with ethanol (3 9 volume) and sodium acetate (1/10th volume), followed by vigorous ethanol (70%) washes. The integrity of the RNA was evaluated on an Agilent Bioanalyzer. Poly(A)-tailed RNA was prepared and used to create cDNA libraries for deep sequencing by the Core Facility. Samples were sequenced for 50 cycles on an Illumina HiSeq 2000 sequencer and sequence reads were processed, aligned, analyzed and visualized as previously described by us and others [24, 25, 27] .
RNA-immunoprecipitation (RIP) studies
A Magna RIP RNA-binding protein immunoprecipitation kit (EMD Millipore, Billerica, MA, USA) was used according to the manufacturer's protocol. In brief, platelets were cultured overnight and then lysed in 750 lL of complete RIP lysis buffer. Platelet lysates were subsequently incubated with a specific antibody against RARa (anti-RARa; EMD Millipore) or an isotype-matched nonimmune IgG. The antibodies were pre-conjugated to magnetic beads prior to incubation with platelet lysates. RIP was performed by incubating the antibody-conjugated beads with the supplied buffer (100 lL) and the platelet lysate (100 lL), with constant rotation for 4 h at 4°C. In parallel, RNA was isolated from 100 lL of the lysate, which represented '100% input' for comparative analyses. After the IP reaction, aliquots were removed from each IP sample to test for the efficiency of IP by western blot (see below). Phenol-chloroform isolation techniques were used for RNA purification with an additional overnight ethanol precipitation step. RNA yield was measured using the NanoDrop spectrometer. For cDNA synthesis, the VILO system (Invitrogen) was used with 1 ll of RNA as starting material and random hexamers as reverse primers. The extension reaction time for cDNA synthesis was increased to 2 h for greater yield. For subsequent PCR reactions the IP and input samples were used as positive controls and IgG and PCR reactions as negative controls. In some cases, where sample quantity was insufficient for all necessary experiments, samples were split prior to PCR reactions. The RNA isolated from the IP sample was used for Illumina deep sequencing as described [25] . Sequences with matching consensus binding sequences for RARa were identified in immunoprecipitated mRNAs identified by RNA-sequencing. Candidate mRNAs were assessed using the following primer sequences and reaction conditions: RARa forward 5 
Protein expression studies
Platelets were incubated with atRA or 9cisRA overnight at 37°C, based on prior studies [20] , and supernatants and cell lysates in Laemmli buffer were analyzed. Data were normalized to the cell numbers used in the overnight incubation period. RIP efficiency was determined by western blot where immunoprecipitates were separated by SDS-polyacrylamide gel electrophoresis and examined by western analysis for RARa (EMD Millipore). Western blot was also used to assess the expression of MAP1LC3B2A (anti-MAP1LC3B2A; EMD Millipore). Densitometric quantification and analysis was performed using ImageJ software (NIH, Bethesda, MD, USA).
Studies of de novo protein synthesis
Microscopy-based global protein synthesis studies using Click-IT AHA (L-Azidohomoalanine), and Click-IT AF488 alkyne (1 mM, Lifetechnologies, Eugene, OR, USA) were performed as previously described [6, 7, 21] . For these studies, an average of 850 platelets per treatment arm were analyzed using CellProfiler software (see below for details).
Microscopy and image analysis
Confocal laser microscopy was performed using an Olympus IX81, FV300 (Olympus, Melville, NY, USA) confocal-scanning microscope equipped with a 60x/1.42 NA oil objective for viewing platelets. An Olympus FVS-PSU/ IX2-UCB camera and scanning unit and Olympus Fluoview FV 300 image acquisition software version 5.0 were used for recording. Monochrome 16-bit images were further analyzed and changes quantified using Adobe Photoshop CS6, ImageJ (NIH) and CellProfiler (www. cellprofiler.org) [28, 29] .
In vitro translation of MAP1LC3B2
Custom-synthesized plasmid with the pCMV6-Entry vector as a backbone (BlueHeron, Bothell, WA, USA) and containing full-length MAP1LC3B2 (based on the NCBI standard sequence), including 5 0 -and 3 0 -UTR, was introduced into the 1-step human coupled IVT kit (ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. In select samples, recombinant human RARa (#H00005914-P01, Abnova, Taipei, Taiwan, 100 nM final), atRA (10 lM final), or both (RARa 100 nM and atRA 10 lM), was added to the IVT reaction mix and allowed to incubate for 6 h. Samples were then harvested in Laemmli buffer and prepared for western blot analysis. Freshly isolated platelets were cultured in the presence of an azido-amino acid analog of alanine (AHA), without (top) or with (bottom) atRA. In addition, platelets were pre-incubated with puromycin (AHA + puromycin) or its vehicle (AHA) for 2 h. The platelets were fixed after 6 h and incorporation of the amino acid analog into protein was visualized (green stain). Unlabeled platelets fixed at baseline (left panel) were used to control for background immunofluorescence (Control, scale bar = 10 lm). (B) The bar graph displays the Cell Profiler analysis of the staining intensity for AHA (green) and is expressed as % change over AHA-treated cells (AE SEM; n = 3). Single asterisk: P < 0.05. This figure is representative of three independent experiments.
Statistical analyses
The mean AE SEM was determined for each experimental variable. ANOVA was used to identify differences that existed among multiple experimental groups. If significant differences were found, a Newman-Keuls post-hoc test was used to determine the location of the difference. A two-tailed Pvalue of <0.05 was considered statistically significant.
Results
atRA treatment induces de novo protein synthesis in human platelets
To determine whether atRA alters platelet translational events, we performed metabolic labelling by incubating platelets with Click-IT AHA (L-Azidohomoalanine) [6, 7, 21] in the presence or absence of atRA. Engagement of RARa with its ligand atRA significantly increased the incorporation of labeled AHA into platelets ( Fig. 1A and B). Puromycin (a translational inhibitor and control condition in our experiment) almost completely blocked global protein synthesis (Fig. 1) . These data indicate that atRA treatment and RARa involvement regulate protein synthetic events in platelets.
RARa is directly associated with RARa mRNA in human platelets
Published data demonstrate that RARa protein has the capability to bind its own RNA [30] . To confirm this in our system of human platelets and to use this interaction as a positive control for our platelet-based RNA-IP assay, we first determined if RARa protein binds RARa mRNA in human platelets using a RNA-Co-IP (RIP) approach [31] . After performing RIP using antibodies directed against RARa, IP efficiency was determined by western blot. Figure 2 (A) shows a representative blot demonstrating the specificity and sensitivity of the technique to detect RARa ( Fig. 2A) . We next sought to test the hypothesis that in human platelets, RARa protein binds its mRNA transcript, thus self-regulating its expression. To determine this, we isolated the RNA derived from the RNA-Co-IP and performed PCR experiments. These experiments demonstrated that RARa protein binds its encoding mRNA (Fig. 2B and 2C , IP lane, and bar graph). The positive input control and the negative controls (IgG IP and -PCR) yielded expected and appropriate negative results, demonstrating the specificity of our RIP system.
RARa protein binds additional platelet mRNAs
Previous studies have shown that RARa regulates posttranscriptional gene expression [30] [31] [32] [33] . Therefore, we determined if RARa protein is capable of binding other platelet mRNAs in addition to RARa by RIP analysis. Table 1 illustrates a comprehensive list of transcripts pulled down during our RIP experiments. We found that anti-RARa antibody captured 38 identified mRNAs (and one miRNA) that have consensus RARa binding motifs [31] (Table 1 and Fig. 3A) . Three candidate transcripts with consensus RARa binding sequences, microtubuleassociated protein 1 light chain 3 beta 2 (MAP1LC3B2) [34] , SLAIN motif-containing protein 2 (SLAIN2) [35] and angiopoietin-1 (ANGPT1) [36] , were selected for further study. As shown in Fig. 3(B) , the 3 0 -UTR of MAP1LC3B2 contained two consensus RARa binding sites (CAGTTC and GGAGTG). Two other consensus motifs (CACCTC and GGAGTG) were identified in the annotated 5 0 -UTR of MAP1LC3B2 (data not shown). In addition, two consensus RARa binding motifs (GGTGGG and GGCGGG) were found in the 5 0 -UTR of SLAIN2 (Fig. 3C) . Two additional consensus sites (GGTGGG and CACCTC) were identified in the 3 0 -UTR of the SLAIN2 gene (data not shown). One consensus RARa binding motif (GGAGTG) was found in the 5 0 -UTR of ANGPT1 (Fig. 3D) . Two additional consensus sites were identified in the annotated open reading frame (CAGTTC) and the 3 0 -UTR (CAGTTC) of the ANGPT1 gene (data not shown).
All-trans retinoic acid decreases interactions between SLAIN2 and ANGPT1 mRNA and RARa in platelets PCR analysis confirmed that mRNA precipitates captured by an antibody against RARa, but not its IgG control, contained mRNA for SLAIN2 (Fig. 4A and B) and ANGPT1 ( Fig. 4C and 4D ). In addition, we also found that treating human platelets with atRA decreased binding of SLAIN2 or ANGPT1 mRNA to RARa protein (Fig. 4) .
RARa protein and MAP1LC3B2 mRNA interactions are regulated by all-trans retinoic acid and control MAP1LC3B2 protein expression in platelets PCR analysis confirmed that anti-RARa, but not its IgG control, immunoprecipitates mRNA for MAP1LC3B2 and atRA significantly (P < 0.05) decreased binding of MAP1LC3B2 mRNA to RARa protein ( Fig. 5A and 5B). These results suggested the possibility that atRA regulates MAP1LC3B2 protein expression in platelets. To examine this further, we assessed the expression of MAP1LC3B2 protein in platelets in the presence or absence of atRA. As shown in Fig. 5(C, D) , platelets at baseline (BL) did not express appreciable amounts of MAP1LC3B2 protein. Culturing platelets in the presence of atRA, however, induced robust de novo expression of MAP1LC3B2 protein, whereas 9cisRA (the isomer of atRA) had only a trivial effect ( Fig. 5C and D) . To examine the specificity of RARa in atRA-induced translation, we utilized an in vitro, cell-free protein expression assay with MAP1LC3B as the target mRNA. As shown in Fig. 5(E, F) , in the presence of RARa, atRA significantly increased translation of MAP1LC3B2.
Discussion
In this report we provide the first evidence that the RARa-retinoic acid (RA) signaling pathway is a translational control mechanism in human platelets. A broader understanding of this complex pathway has implications clinically as atRA use in patients is associated with changes in the platelet count, a hypercoagulable state and thrombosis [18, 19] . Specifically, we show that atRA induces global de novo protein synthesis and, in addition, specific expression of MAP1LC3B2 protein in platelets. Because megakaryocytes and platelets express mRNA and protein for RARa, but lack protein for other RAR family members, it is presumed that atRA exerts its primary activity through RARa [20] . Non-genomic roles for RARa have been reported in neuronal cells, where RARa binds a subset of RNAs, thus repressing translation [30] [31] [32] [33] . Binding is mediated by the F-domain in the carboxy terminus of RARa protein and specific sequence motifs in the target mRNAs (see Fig. 3A and [31] ). Treatment of neurons with RA reduces the association of RARa protein with its target mRNA, relieving translational repression [32] . Our results demonstrate that RARa also serves as an RNA-binding protein in platelets. RARa-enriched immunoprecipitates contained numerous mRNAs, as measured by next-generation RNA sequencing ( Table 1) . Many of these RARa-bound mRNAs possess consensus sequence motifs that are recognized by RARa, including MAP1LC3B2, SLAIN2 and ANGPT1. We hypothesize that, similar to neurons, RARa may limit constitutive translation of MAP1LC3B2, SLAIN2 and ANGPT1 transcripts in platelets by directly binding each mRNA. Consistent with this hypothesis, treatment of platelets with atRA, at 10 lM, a concentration which induces cytoskeletal changes in platelets while preserving their general function [20] , reduces these associations, resulting in a concomitant increase in MAP1LC3B2 protein (Fig. 5C  and D) .
SLAIN2 mRNA, not previously identified as being expressed by human platelets, was identified as another mRNA bound by RARa (Fig. 3C, 4A, B) . We demonstrated decreased association of SLAIN2 mRNA and RARa as a result of atRA treatment of platelets.
SLAIN2 is known to link microtubule plus end-tracking proteins, binding to cytoplasmic linker proteins (CLIPs) and CLIP-associated proteins, and controlling microtubule growth [35] . Furthermore, it was demonstrated that invasive growth requires regulated microtubule growth by SLAIN and interaction partners [37] . Future studies should ascertain how atRA signaling regulates SLAIN2 protein expression in platelets, and the function of this protein in health and disease.
Previous studies have shown that platelets constitutively store ANGPT1 and release it upon stimulation with thrombin [36, 38] . ANGPT1 is a growth factor essential for angiogenesis, where it stabilizes endothelial cell proliferation and induces sprouting and lumina formation [39, 40] . Our studies link the RA signaling pathway to ANGPT1 mRNA, which has not previously been demonstrated. Treatment of platelets with atRA decreased the interaction of ANGPT1 mRNA with RARa, indicating a potential translational regulatory function. Translational control has increasingly become recognized as a potential therapeutic area in hemostasis and thrombosis [26, 41, 42] . For example, mammalian target of rapamycin complex 1 (mTORC1), a signaling pathway that controls translation, is the target of therapeutic agents. Disruption of mTORC1 with rapamycin or one of its analogues is being studied in human diseases of thrombosis (or where there is a high risk of thrombosis), including cancer, cardiovascular disease and aging [43, 44] .
Human platelets were not previously known to express MAP1LC3B2 protein, a subunit of neuronal microtubuleassociated MAP1A and MAP1B proteins. MAP1LC3B2 is thought to be involved in neuronal microtubule assembly and neurogenesis [45] . Platelets undergo massive microtubule assembly after they adhere and spread on surfaces, and previous studies from our group demonstrate that they maintain this spread phenotype and respond to agonist stimulation for prolonged periods of time [46] . We have also demonstrated previously that RARa controls regulated actin cytoskeletal functions [20] . However, microtubules are also involved in the formation of progeny, which occurs when platelets are cultured in suspension [21] . Thus, it is possible that the regulated synthesis of MAP1LC3B2 is necessary for prolonged platelet functions involving microtubule assembly and reorganization. In addition, because of the complexity of RAR and RXR heterodimer formation it is possible that a different binding partner of RARa will define its 'flavor' in different signaling events. Our previous [20] and current findings also highlight that protein synthetic responses must be tightly regulated to maintain normal cellular responses. Therefore, dysregulated protein synthesis underpins the pathophysiology of other diseases, including cancer and neurological disorders [47, 48] .
In summary, our findings demonstrate that platelets use RARa-dependent mechanisms to regulate translational events, identifying a previously unknown mechanism of translational control in human platelets. We have dissected in depth three transcripts that are associated with RARa: MAP1LC3B2, SLAIN2 and ANGPT1. In addition, we identified that RARa binds several other platelet mRNAs, suggesting the intriguing possibility that platelets may use RARa to regulate the translation of a subset of mRNAs. Similar to RARa, platelets express other traditional nuclear proteins (e.g. PPAR-c [2] [3] [4] [5] , NFjB [49] and STAT3 [50, 51] ) that are known to modulate transcription in nucleated cells. Future studies may decipher whether RARa also executes its functions by interacting with RXR family members, because they form heterodimers with RAR in other cells [13, 14, 52] , and determine how those diverse interactions modulate the regulatory flavors of RARa. Nevertheless, treatment of platelets with 9cisRA, one of the primary agonists for RXR family members [13] , did not influence the expression of MAP1LC3B2 protein. Whether there is a threshold effect when RARa is modulated by atRA remains unknown. It will also be important to determine if the RAR signaling pathway interfaces with other post-transcriptional gene expression pathways, such as mTOR [26] , Clk1 [6, 7] or Dicer [10] , to regulate hemostasis and thrombosis. Potential roles for the RAR-dependent protein synthesis in megakaryocytes will also be worth investigating, as retinoic acid is critical for cellular differentiation and used for the treatment of promyelocytic leukemia, often resulting in thrombocytosis [18] . 
